Company / Cash & Equivalents
Cytek Biosciences, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$90.9M
FY2025
5-year range
$90.9M / $364.6M
FY2021-FY2025
Trend
-8.0%
vs FY2024
Sector context
#112 of 148
Health Care
What the data says
Cytek Biosciences, Inc.'s cash & equivalents of $91M is lower than 76% of companies in the Health Care sector (FY2025). Cash & Equivalents has declined for 4 consecutive years, from $365M in FY2021 to $91M in FY2025.
Based on SEC 10-K filings.
$91M in FY2025 with a 5-year CAGR of -11.3%.
Declined from $167M to $91M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -32.6%
- 5-Year CAGR
- -11.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 148This company $90.9M Sector average $1.2B
▼
-92.3% below sector average
Key checks
Key Insights
- Cytek Biosciences, Inc.'s cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -11.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 8.0% year-over-year.
- Ranks #112 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $90.9M | -8.0% |
| FY2024 | $98.7M | -41.0% |
| FY2023 | $167.3M | -43.6% |
| FY2022 | $296.6M | -18.7% |
| FY2021 | $364.6M | +120.7% |
| FY2020 | $165.2M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026